SAB Biotherapeutics, Inc. Warrant
SABSW
About: SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Employees: 63
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0.71% less ownership
Funds ownership: 9.34% [Q1] → 8.64% (-0.71%) [Q2]
5% less capital invested
Capital invested by funds: $28.1K [Q1] → $26.7K (-$1.38K) [Q2]
14% less funds holding
Funds holding: 7 [Q1] → 6 (-1) [Q2]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Financial journalist opinion
We haven’t received any recent news articles for SABSW